Sousa A B, Fernandes J P, Costa I, Ferreira G, Nunes O, Ribeiro P, Neves A, Cruz E, Aveiro F, Rodrigues A S, Bernardo M, Conduto A, Gonçalves A J, Monteiro A, Sousa M, Soares V H, Veiga J, Gouveia J
Serviço de Hematologia, Hospital dos Capuchos, Lisboa, Portugal.
Hematol Cell Ther. 1998 Apr;40(2):63-6.
The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.
